We are live on
!
Find out more
AG
Artal Group Portfolio holdings
AUM
$1.01B
1-Year Est. Return
29.84%
This Fund
S&P 500
This Quarter
Est. Return
+29.93%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.38B
AUM Growth
-$1.54B
(-39%)
Cap. Flow
-$2.13B
Cap. Flow
% of AUM
-89.3%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
112
New
–
Increased
–
Reduced
2
Closed
110
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CAVA Group
CAVA
|
+$610M |
| 2 |
Scholar Rock
SRRK
|
+$93.8M |
| 3 |
Kymera Therapeutics
KYMR
|
+$89.7M |
| 4 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$86.1M |
| 5 |
Arrowhead Research
ARWR
|
+$82.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 91.02% |
| 2 | Healthcare | 8.98% |
| 3 | Communication Services | 0% |
| 4 | Real Estate | 0% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CAVA Group
CAVA
$7.61B
| $2.17B | 91.02% |
17,507,990
-6,000,000
| -26% | -$610M |
|
2
Lexicon Pharmaceuticals
LXRX
$1.03B
| $214M | 8.98% |
136,180,481
-38,918,903
| -22% | -$69.3M |
|
3
Adobe
ADBE
$105B
| – | – |
-900
| Closed | -$500K |
|
4
ADC Therapeutics
ADCT
$140M
| – | – |
-1,018,461
| Closed | -$3.22M |
|
|
AGEN
5
Agenus
AGEN
$276M
| – | – |
-775,000
| Closed | -$13M |
|
6
Amazon
AMZN
$2.44T
| – | – |
-19,250
| Closed | -$3.72M |
|
|
APLS
7
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-1,467,080
| Closed | -$56.3M |
|
|
APLT
8
DELISTED
Applied Therapeutics
APLT
| – | – |
-1,009,500
| Closed | -$4.71M |
|
|
9
CALL
Arrowhead Research
ARWR
$12.1B
| – | – |
-1,000,000
| Closed | -$26M |
|
|
10
Arrowhead Research
ARWR
$12.1B
| – | – |
-3,189,389
| Closed | -$82.9M |
|
11
Ascendis Pharma A/S
ASND
$16.5B
| – | – |
-101,100
| Closed | -$13.8M |
|
|
JBIO
12
Jade Biosciences
JBIO
$1.18B
| – | – |
-23,131
| Closed | -$1.34M |
|
13
Black Diamond Therapeutics
BDTX
$95.1M
| – | – |
-1,046,517
| Closed | -$4.88M |
|
14
KE Holdings
BEKE
$17.7B
| – | – |
-225,000
| Closed | -$3.18M |
|
15
Biohaven
BHVN
$2.02B
| – | – |
-306,703
| Closed | -$10.6M |
|
16
Kanzhun
BZ
$7.19B
| – | – |
-50,000
| Closed | -$941K |
|
|
CCC
17
CCC Intelligent Solutions
CCC
$3.55B
| – | – |
-50,000
| Closed | -$556K |
|
|
CFLT
18
DELISTED
Confluent
CFLT
| – | – |
-19,000
| Closed | -$561K |
|
19
Cullinan Oncology
CGEM
$1.06B
| – | – |
-1,057,949
| Closed | -$18.5M |
|
|
CNTA
20
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-2,112,500
| Closed | -$19.1M |
|
21
Caribou Biosciences
CRBU
$146M
| – | – |
-105,347
| Closed | -$173K |
|
22
Crinetics Pharmaceuticals
CRNX
$8.88B
| – | – |
-1,066,064
| Closed | -$47.7M |
|
23
Cyclerion Therapeutics
CYCN
$15.2M
| – | – |
-117,643
| Closed | -$271K |
|
24
Cytokinetics
CYTK
$10.6B
| – | – |
-494,421
| Closed | -$26.8M |
|
25
Datadog
DDOG
$94B
| – | – |
-28,925
| Closed | -$3.75M |
|
Similar funds
BCM
GA
EPAM
WA
CT
AH
PIM
MAM
Artal Group's Q3 2024 Portfolio in Review
As of Q3 2024, Artal Group held 112 positions worth $2.38B, down 39% from $3.92B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Artal Group withdrew a net $2.13B in Q3 2024, closing 110 positions and reducing 2 holdings. Its most notable exit was Scholar Rock, an estimated $93.8M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 91% of assets, up from 56% a quarter earlier, followed by Healthcare and Communication Services.
- Artal Group's biggest Q3 2024 reduction was CAVA Group, cutting an estimated $610M.
- Artal Group fully exited Scholar Rock in Q3 2024, selling an estimated $93.8M.
- Artal Group's ten largest holdings make up 100% of its $2.38B portfolio in Q3 2024.
- Artal Group opened 0 new positions and closed 110 in Q3 2024.
- Artal Group's portfolio value fell 39% quarter-over-quarter to $2.38B.
Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.